Michael Overman

39PUBLICATIONS
245CO-AUTHORS
Medical infection agents (incl. prions)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Medical molecular engineering of nucleic acids and proteinsMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (39)

|Nov 18, 2025
Prognosis and treatment response stratification according to loss of proofreading (LOP) POLE variants.

Giulia Maddalena, Fadl A Zeineddine, Saikat Chowdhury

|Nov 14, 2025
Impact of RAS/BRAFV600E Mutations on the Tumor Immune Microenvironment in Mismatch Repair-Deficient/Microsatellite Instability Colorectal Cancers.

Mohamed E Salem, Alberto Puccini, Elizabeth Mauer

|Jul 16, 2025
Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT.

Andrew J Pellatt, Alisha Bent, Nicholas Hornstein

|Feb 10, 2025
Sex and outcomes of patients with microsatellite instability-high and BRAF V600E mutated metastatic colorectal cancer receiving immune checkpoint inhibitors.

Vincenzo Nasca, Joseph Zhao, Javier Ros

|Jan 06, 2025
Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial.

Kanwal Pratap Singh Raghav, Katherine A Guthrie, Benjamin Tan

|Jan 04, 2025
Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitors.

Julien Taieb, Margherita Ambrosini, Emily Alouani

Pageof 7

Frequent Collaborators

9 joint publications

Kanwal Raghav

8 joint publications

Scott Kopetz

7 joint publications

N Arvind Dasari

7 joint publications

John Paul Shen